Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared wit
Go back to Eledon Presents Long-Term Extension Phase 2 BESTOW Results at American Transplant Congress Showing Sustained Higher Kidney Function and Improved Patient-Reported Outcomes with Tegoprubart Compared wit| (NASDAQ: ELDN) | Delayed: 2.62 -0.03 (1.13%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.65 | 52 Week High | $ | |||
| Open | $2.67 | 52 Week Low | $ | |||
| Day High | $2.68 | P/E | N/A | |||
| Day Low | $2.57 | EPS | $ | |||
| Volume | 828,838 | |||||
